Step by Step

INTRODUCTION

ABIM MOC Activity ID

6/4/2021 - Medical Grand Rounds: Lung Cancer Chemoprevention Implications For Early Carcinogenesis

QUIZ

EVALUATION

CERTIFICATE

INTRODUCTION

Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Describe and improve lung cancer screening utilization and evaluate the breadth of lung cancer morbidity and mortality.
  • Implement and summarize the results of lung cancer chemoprevention trials to date.
  • Identify ways to reduce cancer recurrence and examine the role of targeted lung cancer chemoprevention trials and results.

Suggested Additional Reading & Joint Accreditation Statement:

Suggested additional reading:

  1. Keith RL, Miller YE, Hudish TM, Girod CE, Sotto-Santiago S, Franklin WA, Nemenoff RA, March TH, Nana-Sinkam SP, Geraci MW. Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice. Cancer Res. 2004 Aug 15;64(16):5897-904. PMID: 15313935
  2. Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn PA Jr, Johnson GL, Hirsch FR, Merrick DT, Franklin WA, Baron AE, Keith RL, Nemenoff RA, Malkinson AM, Geraci MW. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. Am J Pathol. 2005 Dec;167(6):1763-75. PMID: 16314486, PMCID: PMC1613183
  3. Nana-Sinkam SP, Lee JD, Sotto-Santiago S, Stearman RS, Keith RL, Choudhury Q, Cool C, Parr J, Moore MD, Bull TM, Voelkel NF, Geraci MW. Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke. Am J Respir Crit Care Med. 2007 Apr 1;175(7):676-85. Epub 2007 Jan 25. PMID: 17255567, PMCID: PMC1899287
  4. Nemenoff R, Meyer AM, Hudish TM, Mozer AB, Snee A, Narumiya S, Stearman RS, Winn RA, Weiser-Evans M, Geraci MW, Keith RL. Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator--activated receptor gamma. Cancer Prev Res (Phila). 2008 Oct;1(5):349-56. doi: 10.1158/1940-6207.CAPR-08-0145. PMID: 19138979, PMCID: PMC2680197
  5. Nakachi I, Rice JL, Coldren CD, Edwards MG, Stearman RS, Glidewell SC, Varella-Garcia M, Franklin WA, Keith RL, Lewis MT, Gao B, Merrick DT, Miller YE, Geraci MW. Application of SNP microarrays to the genome-wide analysis of chromosomal instability in premalignant airway lesions. Cancer Prev Res (Phila). 2014 Feb;7(2):255-65. doi: 10.1158/1940-6207.CAPR-12-0485. Epub 2013 Dec 17. PMID: 24346345, PMCID: PMC3926809
  6. Merrick DT, Edwards MG, Franklin WA, Sugita M, Keith RL, Miller YE, Friedman MB, Dwyer-Nield LD, Tennis MA, O'Keefe MC, Donald EJ, Malloy JM, van Bokhoven A, Wilson S, Koch PJ, O'Shea C, Coldren C, Orlicky DJ, Lu X, Baron AE, Hickey G, Kennedy TC, Powell R, Heasley L, Bunn PA, Geraci M, Nemenoff RA. Altered Cell-Cycle Control, Inflammation, and Adhesion in High-Risk Persistent Bronchial Dysplasia. Cancer Res. 2018 Sep 1;78(17):4971-4983. doi: 10.1158/0008-5472.CAN-17-3822. Epub 2018 Jul 11. PMID: 29997230, PMCID: PMC6147150
  7. Geraci MW. TARGETING THE PROSTACYCLIN/PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AXIS IN LUNG CANCER CHEMOPREVENTION. Trans Am Clin Climatol Assoc. 2018;129:48-55. PMID: 30166698, PMCID: PMC6116597
  8. Keith RL, Blatchford PJ, Merrick DT, Bunn PA, Bagwell B, Dwyer-Nield LD, Jackson MK, Geraci M, Miller YE. A Randomized Phase II Trial of Pioglitazone for Lung Cancer Chemoprevention in High Risk Current and Former Smokers. Cancer Prev Res (Phila). 2019. Epub 2019/07/17. doi: 10.1158/1940-6207.CAPR-19-0006. PubMed PMID: 31308004.

Joint Accreditation Statement
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit[s]™. Physicians should only claim credit commensurate with the extent of their participation in the activity. This educational activity is approved for 1.0 contact hours.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Authors:
Mark W. Geraci, MD — Associate Vice Chancellor for Interdisciplinary Research, Health Sciences, Professor of Medicine, School of Medicine, University of Pittsburgh
Dr. Geraci has disclosed he has a licensed intellectual property to VisionGate, Inc.
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The University of Pittsburgh is an affirmative action, equal opportunity institution.